$10.15
0.00%
Nasdaq, Mon, Sep 08 2025
ISIN
US46565G1040
Symbol
ITOS

ITeos Therapeutics Inc Stock price

$10.15
+0.04 0.40% 1M
+3.20 46.04% 6M
+2.47 32.16% YTD
-5.41 34.77% 1Y
-11.35 52.79% 3Y
-16.87 62.44% 5Y
-8.90 46.72% 10Y
-8.90 46.72% 20Y
Nasdaq, Closing price Mon, Sep 08 2025
+0.00 0.00%
ISIN
US46565G1040
Symbol
ITOS
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$515.4m
Shares outstanding
38.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
85.9%
Return on Equity
-22.8%
ROCE
-30.0%
ROIC
-177.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-164.3m | $-125.5m
EBIT
$-165.6m | $-179.9m
Net Income
$-167.8m | $-137.0m
Free Cash Flow
$-108.8m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
-14.3% | 20.7%
EBIT
-14.3% | -12.8%
Net Income
-55.2% | -1.9%
Free Cash Flow
7.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.9
FCF per Share
$-2.8
Short interest
5.8%
Employees
173
Rev per Employee
$200.0k
Show more

Is ITeos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

ITeos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a ITeos Therapeutics Inc forecast:

7x Hold
70%
3x Sell
30%

Analyst Opinions

10 Analysts have issued a ITeos Therapeutics Inc forecast:

Hold
70%
Sell
30%

Financial data from ITeos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
32% 32%
-
- Research and Development Expense 131 131
1% 1%
-
-164 -164
14% 14%
-
- Depreciation and Amortization 1.29 1.29
16% 16%
-
EBIT (Operating Income) EBIT -166 -166
14% 14%
-
Net Profit -168 -168
55% 55%
-

In millions USD.

Don't miss a Thing! We will send you all news about ITeos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ITeos Therapeutics Inc Stock News

Neutral
PRNewsWire
25 days ago
NEW YORK , Aug. 20, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iTeos Therapeutics, Inc. (NASDAQ: ITOS)'s  sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire ...
Neutral
GlobeNewsWire
26 days ago
NEW YORK and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iTeos Therapeutics, Inc. (NasdaqGM: ITOS) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of iTeos will receive $10.047 in cash per share, plu...
Neutral
Business Wire
about 2 months ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iTeos Therapeutics, Inc. (NasdaqGM: ITOS) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of iTeos will receive $10.047 in cash per share, plus one non-tran...
More ITeos Therapeutics Inc News

Company Profile

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.

Head office United States
CEO Michel Detheux
Employees 173
Founded 2012
Website www.iteostherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today